Ozempic Face, Blindness Claims, And Billions In Potential Damages: The GLP-1 Reckoning

A surge in demand for GLP-1 receptor agonist drugs such as Ozempic has transformed them from treatments primarily for type 2 diabetes into popular weight-loss medications, fueling shortages, cultural trends, and now thousands of lawsuits alleging serious side effects. Novo Nordisk’s Ozempic (semaglutide) and similar drugs from Eli Lilly have seen prescriptions explode, with off-label […]
The post Ozempic Face, Blindness Claims, And Billions In Potential Damages: The GLP-1 Reckoning appeared first on Dallas Express.
💡 AI analysis provides alternative perspectives on current events